To observe the effect of enhanced lipid lowering therapy on blood lipid, inflammatory factors, and prognosis in patients with acute cerebral infarction (ACI).

88 cases of ACI from January 2016 to December 2016 were selected as the research object, and were divided into two groups according to the random number table method, 44 cases in each group. The control group was treated with 20 mg/d atorvastatin, and the observation group was treated with 40 mg/d atorvastatin. The levels of blood lipids, inflammatory factors before and after the treatment, the incidence of adverse reactions, and the prognosis of the two groups were observed.

There were no statistically significant differences in the levels of total cholesterol (TC), triacylglycerol (TG), low density lipoprotein cholesterol (LDL-C), high sensitive C reactive protein (hs-CRP), tumor necrosis factor alpha (TNF- alpha) between the two groups before treatment (P>0.05); after treatment, the levels of TC, TG, LDL-C, hs-CRP, and TNF- alpha of the observation group were lower than those of the control group, with statistically significant differences (P<0.05). The recurrence rate of the control group was higher than that of the observation group, with statistically significant difference (P<0.05). There was no statistically significant difference in the incidence of adverse effects between the two groups (P>0.05).

Intensive lipid-lowering therapy can help to regulate the levels of blood lipids and inflammatory factors in ACI patients, enhance the stability of vulnerable plaques, reduce the risk of recurrence, and enhance the clinical efficacy and prognosis.

Acute cerebral infarction; Enhanced lipid lowering; Blood lipid; Inflammatory factor; Prognosis